BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 16077988)

  • 21. Curcumin sensitizes lung cancer cells to cisplatin-induced apoptosis through superoxide anion-mediated Bcl-2 degradation.
    Chanvorachote P; Pongrakhananon V; Wannachaiyasit S; Luanpitpong S; Rojanasakul Y; Nimmannit U
    Cancer Invest; 2009 Jul; 27(6):624-35. PubMed ID: 19283527
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel titanocene anti-cancer drugs and their effect on apoptosis and the apoptotic pathway in prostate cancer cells.
    O'Connor K; Gill C; Tacke M; Rehmann FJ; Strohfeldt K; Sweeney N; Fitzpatrick JM; Watson RW
    Apoptosis; 2006 Jul; 11(7):1205-14. PubMed ID: 16699961
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of CAY10404 on the PKB/Akt and MAPK pathway and apoptosis in non-small cell lung cancer cells.
    Cho Y; Park MJ; Park M; Min SS; Yee J; Kim C; Han MS; Han SH
    Respirology; 2009 Aug; 14(6):850-8. PubMed ID: 19703066
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cisplatin resistance induced by decreased apoptotic activity in non-small-cell lung cancer cell lines.
    Cetintas VB; Kucukaslan AS; Kosova B; Tetik A; Selvi N; Cok G; Gunduz C; Eroglu Z
    Cell Biol Int; 2012 Mar; 36(3):261-5. PubMed ID: 22397496
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Involvement of Bcl-2 family, cytochrome c and caspase 3 in induction of apoptosis by beauvericin in human non-small cell lung cancer cells.
    Lin HI; Lee YJ; Chen BF; Tsai MC; Lu JL; Chou CJ; Jow GM
    Cancer Lett; 2005 Dec; 230(2):248-59. PubMed ID: 16297711
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Determination of volatile biomarkers for apoptosis and necrosis by solid-phase microextraction-gas chromatography/mass spectrometry: a pharmacometabolomic approach to cisplatin's cytotoxicity to human lung cancer cell lines.
    Pyo JS; Ju HK; Park JH; Kwon SW
    J Chromatogr B Analyt Technol Biomed Life Sci; 2008 Dec; 876(2):170-4. PubMed ID: 19027370
    [TBL] [Abstract][Full Text] [Related]  

  • 27. STI-571 (Gleevec) potentiates the effect of cisplatin in inhibiting the proliferation of head and neck squamous cell carcinoma in vitro.
    Wang-Rodriguez J; Lopez JP; Altuna X; Chu TS; Weisman RA; Ongkeko WM
    Laryngoscope; 2006 Aug; 116(8):1409-16. PubMed ID: 16885745
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of three approaches for inhibiting insulin-like growth factor I receptor and their effects on NSCLC cell lines in vitro.
    Cosaceanu D; Carapancea M; Alexandru O; Budiu R; Martinsson HS; Starborg M; Vrabete M; Kanter L; Lewensohn R; Dricu A
    Growth Factors; 2007 Feb; 25(1):1-8. PubMed ID: 17454144
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cyclooxygenase-2-dependent activation of signal transducer and activator of transcription 3 by interleukin-6 in non-small cell lung cancer.
    Dalwadi H; Krysan K; Heuze-Vourc'h N; Dohadwala M; Elashoff D; Sharma S; Cacalano N; Lichtenstein A; Dubinett S
    Clin Cancer Res; 2005 Nov; 11(21):7674-82. PubMed ID: 16278387
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antitumor activity of a novel recombinant mutant human tumor necrosis factor-related apoptosis-inducing ligand.
    Fang F; Wang AP; Yang SF
    Acta Pharmacol Sin; 2005 Nov; 26(11):1373-81. PubMed ID: 16225761
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nuclear and cytoplasmic death receptor 5 as prognostic factors in patients with non-small cell lung cancer treated with chemotherapy.
    Leithner K; Stacher E; Wurm R; Ploner F; Quehenberger F; Wohlkoenig C; Bálint Z; Polachova J; Olschewski A; Samonigg H; Popper HH; Olschewski H
    Lung Cancer; 2009 Jul; 65(1):98-104. PubMed ID: 19081160
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Acquisition of an enhanced aggressive phenotype in human lung cancer cells selected by suboptimal doses of cisplatin following cell deattachment and reattachment.
    Hsieh JL; Lu CS; Huang CL; Shieh GS; Su BH; Su YC; Lee CH; Chang MY; Wu CL; Shiau AL
    Cancer Lett; 2012 Aug; 321(1):36-44. PubMed ID: 22450752
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The cisplatin-irradiation combination suggests that apoptosis is not a major determinant of clonogenic death.
    Lo Nigro C; Arnolfo E; Taricco E; Fruttero A; Russi EG; Lucio F; Ribero S; Comino A; Merlano M; Ungari S
    Anticancer Drugs; 2007 Jul; 18(6):659-67. PubMed ID: 17762394
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Down-regulation of hepatoma-derived growth factor inhibits anchorage-independent growth and invasion of non-small cell lung cancer cells.
    Zhang J; Ren H; Yuan P; Lang W; Zhang L; Mao L
    Cancer Res; 2006 Jan; 66(1):18-23. PubMed ID: 16397209
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Downregulation of survivin expression enhances sensitivity of cultured uveal melanoma cells to cisplatin treatment.
    Li H; Niederkorn JY; Neelam S; Alizadeh H
    Exp Eye Res; 2006 Jul; 83(1):176-82. PubMed ID: 16584731
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Zoledronic acid is unable to induce apoptosis, but slows tumor growth and prolongs survival for non-small-cell lung cancers.
    Li YY; Chang JW; Chou WC; Liaw CC; Wang HM; Huang JS; Wang CH; Yeh KY
    Lung Cancer; 2008 Feb; 59(2):180-91. PubMed ID: 17900752
    [TBL] [Abstract][Full Text] [Related]  

  • 37. X-radiation induces non-small-cell lung cancer apoptosis by upregulation of Axin expression.
    Han Y; Wang Y; Xu HT; Yang LH; Wei Q; Liu Y; Zhang Y; Zhao Y; Dai SD; Miao Y; Yu JH; Zhang JY; Li G; Yuan XM; Wang EH
    Int J Radiat Oncol Biol Phys; 2009 Oct; 75(2):518-26. PubMed ID: 19735876
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Highly sensitive and selective anticancer effect by conjugated HA-cisplatin in non-small cell lung cancer overexpressed with CD44.
    Quan YH; Kim B; Park JH; Choi Y; Choi YH; Kim HK
    Exp Lung Res; 2014 Dec; 40(10):475-84. PubMed ID: 25299431
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lung carcinomas do not induce T-cell apoptosis via the Fas/Fas ligand pathway but down-regulate CD3 epsilon expression.
    Prado-Garcia H; Aguilar-Cazares D; Meneses-Flores M; Morales-Fuentes J; Lopez-Gonzalez JS
    Cancer Immunol Immunother; 2008 Mar; 57(3):325-36. PubMed ID: 17668204
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Potential mechanism of resistance to TRAIL-induced apoptosis in Burkitt's lymphoma.
    Tafuku S; Matsuda T; Kawakami H; Tomita M; Yagita H; Mori N
    Eur J Haematol; 2006 Jan; 76(1):64-74. PubMed ID: 16343273
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.